SoftOx Solutions AS — Share Issue/Capital Change 2024

Apr 8, 2024

SOFTX: New share capital

SOFTX: New share capital

Not for release, publication or distribution, in whole or in part directly or indirectly, in Australia, Canada, Japan or the United States (or any other jurisdiction in which the release, publication or distribution would be unlawful). This announcement does not constitute an offer of any of the securities described herein.

Reference is made to the stock exchange release from Softox Solutions AS (the "Company") 27 March 2024 regarding share capital increase resolved be the general meeting.

The new share capital following completion of the private placement and the debt conversion has today been registered with the Norwegian Register of Business Enterprises.

The new share capital of the Company is NOK 10 068 473.80 divided on 503 423 690 shares with a nominal value of NOK 0.02 per share.

Note that there is a minimal deviation from the registered (and correct) new share capital and number of shares issued compared to information in the stock exchange release 27 March 2024.

For any questions or interview requests, please contact:

Geir Almås, Chair of SoftOx Solutions AS

Mail: ir@soft-ox.com

Phone: Geir Almås: (+47) 977 59 071

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and is headquartered in Oslo. The SoftOx Solutions Group includes: the holding company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly effective antimicrobial solution for use in biofilm, viral and antimicrobial resistant infections. The patent-protected technology is based on extensive research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com